SecBot SecBot
SC 13G/A ·Filed Nov 10, 2026

LYEL

Lyell Immunopharma, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6d 8h ago SEC0001012975-26-001025
Passive stake amendment
Actionable Insight • Neutral

ARCH's passive stake is unchanged, indicating no shift in investor sentiment. Monitor for any future conversion to a 13D filing, which would signal activist intent, but no such signal is present here.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$16.86
T+0 close · Nov 10, 2026 · via day close
Latest settled
−7.24%
T+1 · $15.64
Vs SPY
−6.88%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $16.86entry
  2. T+1 · 5d ago −7.24%α −6.88% · $15.64
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ARCH Venture Fund IX, L.P. and affiliated entities filed an amended Schedule 13G disclosing a 17.4% passive stake in Lyell Immunopharma as of November 4, 2026, unchanged from the prior filing. The filing confirms the investor remains a passive holder with no change in position or intent, following the company's recent $80M private placement and Q3 earnings report.

Key Financial Metrics

Stake
17.4%
Investor
ARCH Venture Fund IX, L.P.

Key Facts

  • ARCH Venture Fund IX and related entities hold 5,568,424 shares of Lyell Immunopharma common stock, representing 17.4% of shares outstanding as of November 4, 2026.
  • The stake percentage is based on 24,585,565 shares outstanding as of October 30, 2026, plus 7,428,040 shares sold in a private placement on November 4, 2026.
  • The filing is an amendment to Schedule 13G, confirming passive investor status with no change in beneficial ownership from the prior filing.
  • The filing date is November 10, 2026, six days after the company's Q3 2026 earnings release and $80M private placement.

Financial Impact

No change in stake; ARCH's 17.4% holding is valued at approximately $63.5M based on the $365M market cap.

Risk Factors

  • No material risks identified from this filing; the passive stake is routine and unchanged.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001012975-26-001025
Document: 0001012975-26-001025-index.html0001012975-26-001025
Document: 0001012975-26-001025.txt0001012975-26-001025

Track record

21 reports on LYEL

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
  2. Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Viewing Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
  4. Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
  7. Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
  8. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
  9. Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
  10. Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026